We modeled EMT in cultured cancer cells using TGFβ treatment since TGFβ robustly induces EMT in many epithelial cell line models, and physiologically, hyperactivation of TGFβ signaling has been shown to be associated with the mesenchymal phenotype and cancer drug resistance [13, 14]. This evidence concerns the gene TGFB1 and cancer.